

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	X

Xpovio (selinexor)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Xpovio (selinexor)	May be subject to quantity limit

APPROVAL CRITERIA

Requests for Xpovio (selinexor) may be approved if the following criteria are met:

- I. Individual has a diagnosis of relapsed or refractory multiple myeloma; **AND**
 - A. Individual is using in combination with dexamethasone; **AND**
 - B. Individual previously received at least four prior therapies; **AND**
 - C. Confirmation of disease refractory to all of the following:
 1. At least two proteasome inhibitors (for example, bortezomib, carfilzomib, or ixazomib); **AND**
 2. At least two immunomodulatory agents (for example, lenalidomide, pomalidomide, or thalomid); **AND**
 3. An anti-CD38 monoclonal antibody (for example, daratumumab).

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

Key References:

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2019. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: July 19, 2019.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2019; Updated periodically.

PAGE 1 of 2 08/21/2019
New Program Date 08/21/2019

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

CRX-ALL-0434-19

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	X

5. NCCN Clinical Practice Guidelines in Oncology™. © 2019 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed on July 19, 2019.
 - a. Multiple Myeloma. V3.2019. Revised June 19, 2019.
6. NCT02336815. U.S. National Library of Medicine, ClinicalTrials.gov website. <https://clinicaltrials.gov/ct2/show/NCT02336815?term=nct02336815&rank=1>. Accessed July 19, 2019.
7. Vogl DT, Dingli D, Cornell RF, et al. Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma. J Clin Onc 2018 Mar;36(9):859-866.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.